arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nuvation Bio Inc.

NUVB
$4.18 ▼ -0.54 (-11.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuvation Bio Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5M
Dividend Yield —
Revenue Growth 555.6% ↘
Op. Margin -161.1% ↘
ROIC -10.3% ↘
FCF / Share $-123.20 ↘
Trailing P/E —
Price / Book 5.7x
FCF Yield —
Debt / Equity 0.98
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.69M
↑ +555.6% —
Net Income Profit after all expenses
$5.40M
— 0.0% —
Operating Margin Operating profit as % of sales
-161.1%
↓ -3554.0% 0th
FCF / Share Free cash flow per share
$-123.20
↓ -944.2% —
Long-Term Debt Long-term obligations
$242.62M
↑ +412.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns ↓
13
Financial Health ↑
45
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters